Comparing Elekta (OTCMKTS:EKTAY) & NeurAxis (NASDAQ:NRXS)

Elekta (OTCMKTS:EKTAY) and NeurAxis (NASDAQ:NRXS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Elekta and NeurAxis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elekta	0	1	0	0	2.00
NeurAxis	0	1	1	0	2.50

NeurAxis has a consensus price target of $13.00, indicating a potential upside of 82.33%. Given NeurAxis’ stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than Elekta.

Volatility & Risk

Elekta has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider & Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. 41.3% of Elekta shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Elekta and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elekta	-2.38%	13.47%	3.84%
NeurAxis	-492.76%	N/A	-641.25%

Earnings & Valuation

This table compares Elekta and NeurAxis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elekta	$1.78 billion	1.22	-$55.38 million	($0.12)	-49.33
NeurAxis	$5.32 million	16.84	-$14.63 million	($0.78)	-9.14

NeurAxis has lower revenue, but higher earnings than Elekta. Elekta is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Summary

NeurAxis beats Elekta on 8 of the 14 factors compared between the two stocks.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.